Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shenzhen Edge Medical CoFRA:R5Z -0.96%20 Debt-to-EBITDA is 0.39 as of Dec. 2025. GuruFocus rates FRA:R5Z with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 474 Medical Devices & Instruments companies, Shenzhen Edge Medical Co ranks worse than 210970.25% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Shenzhen Edge Medical Co's Debt-to-EBITDA or its related term are showing as below:
FRA:R5Z'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.16 Med: -0.14 Max: -0.1
Current: -0.16
During the past 3 years, the highest Debt-to-EBITDA Ratio of Shenzhen Edge Medical Co was -0.10. The lowest was -0.16. And the median was -0.14.
FRA:R5Z's Debt-to-EBITDA is ranked worse than 100% of 474
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs FRA:R5Z: -0.16
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Shenzhen Edge Medical Co Debt-to-EBITDA Related Terms
Shenzhen Edge Medical Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Edge Medical Co Debt-to-EBITDA Chart
Shenzhen Edge Medical Co Annual Data
Trend
Dec23
Dec24
Dec25
Debt-to-EBITDA
-0.14
-0.10
-0.16
Shenzhen Edge Medical Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Debt-to-EBITDA
N/A
0.00
-0.13
-0.09
0.39
FRA:R5Z vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Shenzhen Edge Medical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Edge Medical Co Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shenzhen Edge Medical Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Shenzhen Edge Medical Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Shenzhen Edge Medical Co (FRA:R5Z) has a Debt-to-EBITDA of 0.39 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Shenzhen Edge Medical Co. According to the industry distribution chart, Shenzhen Edge Medical Co ranks #999999 out of 474 companies in the Medical Devices & Instruments industry.
Is Shenzhen Edge Medical Co's Debt-to-EBITDA too high?
Shenzhen Edge Medical Co's current Debt-to-EBITDA is 0.39. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.63. Shenzhen Edge Medical Co's value of 0.39 is 76.1% below this industry median. Based on the distribution chart, Shenzhen Edge Medical Co ranks #999999 out of 474 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Shenzhen Edge Medical Co has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Edge Medical Co's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shenzhen Edge Medical Co ranks #999999 out of 474 companies for Debt-to-EBITDA. This places Shenzhen Edge Medical Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. Shenzhen Edge Medical Co's value of 0.39 is 76.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 474 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen Edge Medical Co's current Debt-to-EBITDA of 0.39 is 76.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Shenzhen Edge Medical Co. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Edge Medical Co's current Debt-to-EBITDA is 0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Edge Medical Co stock overvalued right now?
Shenzhen Edge Medical Co (FRA:R5Z) has a current Debt-to-EBITDA of 0.39. The current Debt-to-EBITDA is 0.39 and 76.1% below the Medical Devices & Instruments industry median of 1.63. Shenzhen Edge Medical Co's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Shenzhen Edge Medical Co (FRA:R5Z), the current Debt-to-EBITDA is 0.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shenzhen Edge Medical Co Ltd is principally engaged in the designing, research and development, manufacturing and sale of surgical robots. It has a pipeline of three products and product candidates covering various models at different development stages to capture the market potential in surgical robots, including Edge Multi-Port Endoscopic Surgical Robot and Edge Single-Port Endoscopic Surgical Robot for MIS, as well as Edge Bronchoscope Robot for non-invasive surgery. The company derives revenue principally from the sales of surgical robot systems, instruments and accessories, and provision of services. Geographically, the maximum revenue is generated from the Chinese mainland, followed by Asia (other than Chinese Mainland), Europe, and Others.
20GF Score
Get the complete analysis for FRA:R5Z
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:R5Z has been successfully added to your 
